ReviewHuman

Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound

Biomolecules, 2022 Oct 2. Baazaoui N, Iqbal K.

Study type

Review

Subjects

Human participants (PubMed MeSH: Humans)

Journal

Biomolecules

Published

2022 Oct 2

PubMed

PMID 36291618 ↗

DOI

10.3390/biom12101409 ↗

Full text

Free on PubMed Central (PMC9599095) ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

P21 →

Indexed under

MeSH terms assigned by the National Library of Medicine.

HumansAlzheimer DiseaseBrain-Derived Neurotrophic FactorAmyloid beta-PeptidesNeurodegenerative DiseasesFibroblast Growth Factor 2

Other papers on P21

Journal article · 2021

Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction

Journal article · 2017

Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound

Journal article · 2014

Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page